Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Uncontrolled, Open-label Trial to Investigate the Long-term Tolerability, Safety, and Efficacy of Brexpiprazole Once-weekly (QW) Formulation Administered Once Weekly for 52 Weeks in Patients With Schizophrenia

NCT05326347 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05326347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05326347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Uncontrolled, Open-label Trial to Investigate the Long-term Tolerability, Safety, and Efficacy of Brexpiprazole Once-weekly (QW) Formulation Administered Once Weekly for 52 Weeks in Patients With Schizophrenia
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2022
Completion date
September 30, 2025
Enrollment
247 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia